Compare GHG & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
GreenTree Hospitality Group Ltd. American depositary shares each representing one ordinary share
Current Price
Current Price
| Metric | GHG | CDXS |
|---|---|---|
| Founded | 2004 | 2002 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Major Chemicals |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 171.6M | 141.8M |
| IPO Year | 2017 | 2008 |
| Metric | GHG | CDXS |
|---|---|---|
| Price | $1.34 | $1.25 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 22.0K | ★ 1.5M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 3.81% | N/A |
| EPS Growth | N/A | ★ 20.54 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $138,590,000.00 |
| Revenue This Year | $19.02 | $15.64 |
| Revenue Next Year | $8.26 | $5.23 |
| P/E Ratio | $5.76 | ★ N/A |
| Revenue Growth | N/A | ★ 32.30 |
| 52 Week Low | $1.32 | $0.96 |
| 52 Week High | $2.83 | $3.87 |
| Indicator | GHG | CDXS |
|---|---|---|
| Relative Strength Index (RSI) | 32.79 | 49.23 |
| Support Level | N/A | $1.17 |
| Resistance Level | $2.29 | $1.24 |
| Average True Range (ATR) | 0.04 | 0.10 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 15.38 | 77.41 |
GreenTree Hospitality Group Ltd is a franchised hotel operator in China as franchised and managed hotels represent almost all the hotels in its hotel network. The hotel network of the company comprised approximately 4,059 hotels with nearly 302,497 rooms in China, covering all centrally administrated municipalities and cities throughout all provinces and autonomous regions in China. The company operates its hotels under GreenTree Inns, GreenTree Eastern, Gme, Gya and VX, GreenTree Alliance, Vatica, and others. The company operates solely in China and generates all its revenue from China itself.
Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.